Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice

International Journal of Radiation Oncology, Biology, Physics

Volumn 21, Issue 2, 1991, Pages 387-395

  Cole, S ^a   Stratford, I J ^a   Bowler, J ^a   Nolan, J ^a   Wright, E G ^a   Lorimore, S A ^a   Adams, G E ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Bioreductive drugs; Hypoxic cells; Nitroimidazoles; Radiosensitization

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOSENSITIZATION;

ADMINISTRATION, ORAL; ANIMAL; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C3H; MISONIDAZOLE; NEOPLASM TRANSPLANTATION; NITROIMIDAZOLES; RADIATION-SENSITIZING AGENTS; SARCOMA, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T;

EID: 0025826381     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(91)90787-5     Document Type: Article

References (36)

1. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo
2. RSU 1069, a 2-nitroimidazole containing an alkylating group: High efficiency as a radio- and chemosensitizer in vitro and in vivo
3. Electron-affinic sensitization, VII. A correlation between structure, one-electron reduction potentials and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers
4. The in vitro sensitivities to radiation and misonidazole of mouse bone marrow cells derived from different micro-environments
5. Variation of the radiosensitizing efficiency of RSU 1069 with pre-irradiation contact time: A rapid-mix study
6. Characterization of the factor in L-cell conditioned medium capable of stimulating colony formation by mouse marrow cells in culture
7. The growth of mouse bone marrow cells in vitro
8. Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles
9. Radiosensitization and pharmacokinetics of oral and intraperitoneal misonidazole and desmethylmisonidazole in murine tumors
10. Dual function 2-nitroimidazoles and hypoxic cell radiosensitizers and bioreductive cytotoxins: In vivo evaluation in KHT murine sarcomas
11. The development of an oral pro-drug, SR-2545 of the 2nitroimidazole radiosensitizer SR-2508
12. Phase I trial of the hypoxic radiosensitizer SR 2508 the results of the 5–6 week schedule
13. The Courtenay clonogenic assay
14. Studies of the in vivo and in vitro cytotoxicity of the drug RSU 1069
15. Toxicity of RSU 1069 for KHT cells treated in vivo or in vitro: evidence for a diffusible toxic product
16. A toxicity and pharmacokinetic study in man of the hypoxic cell radiosensitizer RSU 1069
17. Synthesis and evaluation of I-(3-(2-haloethylamino)propyl)-2-nitrimidazoles as prodrugs of RSU 1069 and its analogs which are radiosensitizers and bioreductively activated cytotoxins
18. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors
19. Anti-emetics and cancer chemotherapy
20. The route of absorption of intraperitoneally administered compounds
21. Radiosensitization by a new nucleoside analogue 1-[2-hydroxy-l-(hy droxymethyl) ethoxy]methyl-2 nitroimidazole (RP-170)
22. Mechanism of action of some bioreducible 2-nitroimidazoles: Comparison of in vitro cytotoxicity and ability to induce DNA strand breakage
23. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro 07-0582, NSC #261037)
24. The effect of stem cell proliferation regulators demonstrated with an in vitro assay
25. The cloning of normal “mast” cells in tissue culture
26. Hypoxic cell radiosensitization and local control by X-ray of a transplanted tumor in mice
27. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo
28. Potentiation of the anti-tumour effect of melphalan by the vaso-active drug, hydralazine
29. RSU 1069 a nitroimidazole containing an aziridine group Bioreduction greatly increases cytotoxicity under hypoxic conditions
30. The differential cytotoxicity of RSU 1069: Cell survival studies indicating interaction with DNA as a possible mode of action
31. An in vivo assay to measure the viability of KHT tumor cells not previously exposed to culture conditions
32. Pharmacokinetics and metabolism of the mixed function hypoxic cell sensitizer prototype RSU-1069 in mice
33. 3H] isotopomers of RSU 1069 and Ro 03-8799 (pimomidazole)
34. Studies on the toxicity of RSU 1069
35. Differentiation of mouse bone marrow precursor cells into neutrophilic granulocytes by an activity separated from WEHI-3 cell conditioned medium
36. Microcolony survival assay for cells of the mouse intestinal mucosa exposed to radiation